Blog

Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like infliximab, has long been challenged by issues such as antibody formation, variable drug clearance, and the high costs associated with frequent dosing.…

Inflammatory Bowel Disease (IBD) management, particularly with biologic therapies like Infliximab (IFX), presents numerous challenges for gastroenterologists. Despite the widespread use of IFX, a significant proportion of patients experience a loss of…

TuMinimize™ enables oncologists to deliver optimal drug dosing for each patient Fort Myers, FL – June 18, 2024 — Baysient®, a leading provider of therapeutic drug monitoring (TDM) software, today announced the…

A Fresh Perspective on Dosing for Biologic Agents We are excited to announce the publication of “Getting the Dose Right” - Revisiting the Topic with Focus on Biologic Agents in the Clinical…

Inflammatory Bowel Disease (IBD) presents a significant treatment challenge for gastroenterologists worldwide. While biologic therapies have emerged as a cornerstone in managing these complex gastrointestinal conditions, their effectiveness is often hampered by…

In a significant stride for improving oncology treatment, Baysient® has announced its latest innovation: a groundbreaking therapeutic drug monitoring (TDM) software tailored for oncology drugs, coming soon in 2024. This TDM solution…

The complexities of Psoriatic Arthritis (PsA) demand a tailored approach to treatment. With the diverse patient responses to medications, a one-size-fits-all strategy is not viable. Enter Baysient’s groundbreaking software applications, iDose® and…

In an era where personalized medicine is to become the rule rather than the exception, pharmacokinetic (PK)-guided dosing is emerging as a crucial practice for enhancing treatment outcomes. Despite its potential to…

The treatment of rheumatoid arthritis (RA) can no longer be viewed as a one-size-fits-all approach. Each patient's individual characteristics and responses to medication can dramatically influence their treatment outcome. As a result,…

Gastroenterologists often face challenges in managing complex gastrointestinal conditions like ulcerative colitis and Crohn's disease. The key to successful treatment often lies in precision dosing and personalized medicine. Baysient's iDose® and T3®…

Built to provide individualized treatments for patients with improved outcomes, Baysient develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products. Physicians can harness the power…

The COVID-19 pandemic has taken a toll on patients and healthcare providers alike, but for patients with inflammatory diseases treated with therapeutic monoclonal antibodies (mAbs), it poses an additional challenge. Baysient's Chief…

Baysient announces updates to its therapeutic drug monitoring app Time To Target (T3) to enable clinicians to deliver personalized dosing recommendations for the subcutaneous forms of Infliximab and adalimumab. Inflammatory bowel disease…

The right dose at the right time is critical for any patient living with a disease. Precision dosing has become a widely discussed topic, and a growing literature recognizes the implications of imprecise…

For patients living with inflammatory bowel disease (IBD), Infliximab (IFX), a monoclonal antibody, has emerged as an efficient treatment for disease activity reduction and IBD patient life quality improvement. However, while IFX…

Pediatric inflammatory bowel disease (IBD) is a debilitating chronic condition that affects the gastrointestinal tract of children. The symptoms are similar to adults with IBD, but due to the developing immune system,…

Blood tests are critical in the medical field for a variety of reasons. Specifically, blood tests can help doctors evaluate how well the organs are working, diagnose diseases, and assess how well…

Baysient’s web-based applications, iDose and T3 were specifically developed to facilitate the dosing of biological agents by integrating real patient’s clinical characteristics. Both softwares use Bayesian models, routine lab results, and demographics…

IV Infliximab, a monoclonal antibody, has emerged as an efficient treatment with many clinical benefits, such as quick disease activity reduction and IBD patient life quality improvement. However, drug development of infliximab…

Dr. Marla Dubinsky discusses the unique, personalized, and integrated care offered for children at the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center in a video posted by Mount Sinai Health…

Ankylosing Spondylitis Awareness Month is observed every April. This month is dedicated to raising awareness and recognizing arthritis and other associated illnesses such as ankylosing spondylitis.  What is Ankylosing Spondylitis? Ankylosing spondylitis,…

The right dose of medicine is crucial when it comes to the treatment process. For patients with inflammatory bowel disease (IBD), the wrong dose can cause patients to lose response to Infliximab…

Precision dosing focuses on the individualization of drug treatment regimens based on drug attributes, pharmacokinetic/pharmacodynamic variability, disease state characteristics, and patient-specific factors. Before precision dosing, pharmaceutical medicine adopted a one-size-fits-all approach that…

Inflammatory bowel disease (IBD) describes a group of disorders that cause the intestines to become inflamed. There are two main types of IBD: ulcerative colitis and Crohn’s disease. These two types of…

Inflammatory bowel disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. The two main types of IBD are Crohn’s disease (CD) and ulcerative…

Inflammatory bowel disease (IBD), is primarily composed of Crohn’s disease (CD) and ulcerative colitis (UC) and affects as many as 1.6 million Americans, with approximately 30,000 new cases diagnosed each year. Both…

Model-informed precision dosing (MIPD)  involves modeling and simulation to predict the necessary drug dose for a given patient based on their individual characteristics that are most likely to improve efficacy and/or lower…

The Institute for Clinical and Economic Review (ICER) systematically reviewed and synthesized existing evidence from clinical studies to assess the comparative clinical effectiveness for targeted immune modulators (TIMs) for moderate-to-severe ulcerative colitis…

Precision dosing focuses on the individualization of drug treatment regimens based on drug attributes, pharmacokinetic/pharmacodynamic variability, disease state characteristics, and patient-specific factors. This concept of dosing offers the hope of optimizing treatment…

Therapy with biologics has brought a paradigm shift in the management of inflammatory bowel disease (IBD). Infliximab (IFX) has remained one of the key drugs for therapy in IBD. Despite Infliximab’s therapeutic…

In a recent podcast on Podcasts360, Adam Cheifetz, MD, a cochair of the virtual Interdisciplinary Autoimmune Summit (IAS) 2020, gave an overview of his presentation on how proactive and reactive therapeutic drug…

Marla Dubinsky, MD, Discusses Patient Success with Dashboard-Guided Infliximab Induction in Gastroenterology & Endoscopy News Article Baysient’s patented iDose system uses Bayesian models, laboratory data, and demographics to individualize Infliximab dosing, effectively…

For many years, Crohn’s disease and IBD went widely misunderstood and unrecognized. In fact, early doctors could not differentiate between IBD and diarrheal diseases caused by infectious agents. It wasn’t until 1932…

When it comes to drug therapy, there is no one right dose for all patients. Each patient is unique and deserves individual treatments tailored specifically for them. Precision dosing has been shown…

Marla Dubinsky, MD, Speaks on Proactive Therapeutic Monitoring During a recent podcast on Podcasts360, Marla Dubinsky, MD, discussed how her research on measuring drug concentrations and anti-drug antibodies along with algorithmic approaches…

Medication plays an essential role in healthcare, but it also is a significant element in the increasing cost of health care. Precision dosing, also referred to as individualized dosing, utilizes drug attributes,…

At Baysient, it is our mission to help patients achieve remission from their inflammatory diseases. The traditional dosing process for such conditions leads to expensive medical costs overall and makes long-term remission…

Inflammatory Bowel Disease (IBD) represents a group of chronic intestinal conditions, such as ulcerative colitis and Crohn’s disease. These disorders cause prolonged inflammation in the digestive tract, leading to uncomfortable and sometimes…

Baysient’s revolutionary iDose software calculates a precise, model-informed dose of medication to help patients reach, and stay in, remission. We understand that all patients are unique and deserve customized therapies to drive…

Coronavirus (COVID-19) is officially a worldwide pandemic as it continues to spread globally. The doctors and researchers on the Baysient team are actively developing treatments for COVID-19 to help end the death…

Ft. Myers FL, February 28, 2020 - Baysient® LLC’s founder, Diane Mould, announces the release of the iDose® software technology platform version 1.0 for infliximab (an anti-inflammatory biologic drug), just before presenting Biologics…